Clinical Trial Update: Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating REGEND001 for idiopathic pulmonary fibrosis has completed; the update confirms completion of the study but does not report efficacy r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• REGEND001

Snippet

Sponsor: Regend Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED